CD8+ positive T cells are considered a critical component of antitumor immune response, and increased levels of CD8+ TILs have previously been reported to be associated with better outcomes in 552 patients with NSCLC.9 The gene discussed is CD8A; the disease is non-small cell lung carcinoma.